NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING LIMITED

Their core work

NIBRT is Ireland's dedicated training and research institute for biopharmaceutical manufacturing — the industrial process of producing biological medicines like vaccines, gene therapies, and therapeutic proteins. They bridge the gap between lab-scale biology and commercial-scale production, training the workforce and developing improved bioprocessing methods. Their work spans upstream process development, single cell analysis for quality control, and manufacturing of advanced therapy medicinal products including cell and gene therapies.

What they specialise in

How they've shifted over time

NIBRT's early H2020 work (2016–2019) centered on established biopharmaceutical manufacturing — therapeutic proteins, vaccines, and oncolytic viruses — plus cancer therapeutics. From 2020 onward, their focus shifted decisively toward next-generation biologics: CRISPR, gene editing, nucleic acid therapies, and immunotherapy. This mirrors the broader industry pivot from traditional monoclonal antibodies toward advanced therapy medicinal products (ATMPs).

NIBRT is positioning itself as a manufacturing and training hub for the next wave of advanced therapies — gene editing, mRNA, and cell therapies — making them a strong partner for anyone scaling these modalities.

How they like to work

NIBRT acts as both a project leader and a specialist contributor. They coordinated 2 of their 4 projects (STACCATO, GLYCOMENDO), showing confidence in leading consortia, while also joining larger training networks as a partner. With 35 unique partners across 13 countries, they maintain a broad European network rather than relying on a small circle of repeat collaborators — useful for consortium builders seeking a well-connected Irish partner.

NIBRT has collaborated with 35 distinct partners across 13 countries, indicating a well-distributed European network. Their participation in Marie Skłodowska-Curie training networks means their connections span both academia and industry across the biopharma sector.

What sets them apart

NIBRT occupies a rare niche: they are not a university, not a company, but a purpose-built national institute dedicated entirely to biopharmaceutical manufacturing training and research. Ireland hosts many of the world's largest biopharma manufacturing plants (Pfizer, Lilly, MSD), and NIBRT serves as the national skills and innovation pipeline for this sector. For consortium builders, NIBRT offers both deep manufacturing process expertise and strong industry connections that most academic partners cannot match.

Highlights from their portfolio

• STACCATO
  Their largest project (EUR 824K, coordinated) — a European Industrial Doctorate linking academic bioprocess research directly to industry training needs.
• NATURE-ETN
  Signals NIBRT's strategic move into next-generation therapies — CRISPR, gene editing, and nucleic acid therapeutics — beyond traditional biologics manufacturing.
• GLYCOMENDO
  An unusual diversification into clinical diagnostics (endometriosis biomarkers), demonstrating glycan analysis capabilities beyond manufacturing.